Mark Hahn - Nov 1, 2022 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Chief Financial Officer
Signature
/s/ Claire Poll, Attorney-in-fact for Mark Hahn
Stock symbol
VRNA
Transactions as of
Nov 1, 2022
Transactions value $
-$749,781
Form type
4
Date filed
11/3/2022, 04:05 PM
Previous filing
Sep 28, 2022
Next filing
Dec 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Tax liability -$728K -455K -2.54% $1.60* 17.5M Nov 1, 2022 Direct F1, F2, F3
transaction VRNA Ordinary Shares Sale -$22K -13.2K -0.08% $1.67* 17.4M Nov 1, 2022 Direct F1, F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units.
F3 The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on October 31, 2022 divided by eight (8).
F4 The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units.
F5 The price reported represents the sale price of the ADSs divided by eight (8).
F6 Consists of (i) 9,413,016 Ordinary Shares underlying RSUs (which are represented by 1,176,627 ADSs); and (ii) 8,032,464 Ordinary Shares underlying 1,004,058 ADSs.